Along with mutations in the classical PDA-associated oncogenes and tumor suppressors like KRAS, TP53, CDKN2A and SMAD4, the sequencing efforts also uncovered mutations in many chromatin modifying enzymes and complexes. The gene discussed is KRAS; the disease is Patent ductus arteriosus.